Analysis: A meta-analysis of Early Results to predict Vaccine efficacy against Omicron

  title={Analysis: A meta-analysis of Early Results to predict Vaccine efficacy against Omicron},
  author={David S. Khoury and Megan Steain and James A. Triccas and Alex Sigal and M. P. Davenport and Deborah Cromer},
In the studies to date, the estimated fold-drop in neutralisation titre against Omicron ranges from 2- to over 20-fold depending on the study and serum tested. Collating data from the se results in a combined estimate of the fold drop in neutralisation titre against Omicron of 9.7 (95%CI 5.5-17.1). We use our previously established model to predict that six months after primary immunisation with an mRNA vaccine, efficacy for Omicron is estimated to have waned to around 40% against symptomatic… 

The value of vaccine booster doses to mitigate the global impact of the Omicron SARS-CoV-2 variant

It is shown that booster doses can have a major impact in mitigating the epidemic peak, although in many settings it remains possible that healthcare capacity could still be challenged.

Using Survey Data to Estimate the Impact of the Omicron Variant on Vaccine Efficacy against COVID-19 Infection

In South Africa, it is observed that the prevalence of COVID-19 in December (with strong presence of Omicron) among the unvaccinated population is comparable to the prevalence during the previous wave (in August-September), in which Delta was the variant with the largest presence.

Clinical and Economic Impact of Differential COVID-19 Vaccine Effectiveness in the United States

The study objective was to determine the clinical and economic impact of differences in effectiveness between mRNA-1273 and BNT162b2 booster vaccinations over one year (2022) in US adults and to explore the impact of COVID-19 incidence in the unvaccinated population and vaccine effectiveness (VE) on model results.

Determinants of passive antibody effectiveness in SARS-CoV-2 infection

This work integrates data from 37 randomised controlled trials to investigate how the timing and dose of passive antibodies predicts protection from SARS-CoV-2 infection and provides a framework for the rational design of future passive antibody prophylaxis and treatment strategies for COVID-19.

COVID-19 Vaccine Booster Strategies in Light of Emerging Viral Variants: Frequency, Timing, and Target Groups

It is found that the more frequently variants emerge, the less the effect boosters will have, regardless of whether administered annually or biannually, and delivering well-timed annual COVID-19 vaccine boosters to all those eligible, prioritising those most vulnerable, can reduce infections and hospital admissions.

Literature screening report COVID-19 vaccines and post-vaccination data: Literature update (13)

It is suggested that partial escape of the Omicron may be a factor to the variant’s milder breakthrough infections in terms of hospitalization, and vaccine effectiveness, booster doses, children vaccination, and new COVID-19 vaccine candidates are addressed.

Effectiveness of Covid-19 vaccines against SARS-CoV-2 Omicron variant (B.1.1.529): A systematic review with meta-analysis and meta-regression

Compared to full dose only, a booster dose addition provides better protection against B. 1.1.529 infection, and it is important to note that the VE estimates decline over time, suggesting the need for a regular Covid-19 booster injection after certain period of time to maintain VE.

Short-term Projections based on Early Omicron Variant Dynamics in England.

Analysis of UK data showing the earliest signatures of the Omicron variant and mathematical modelling that uses the UK data to simulate the potential impact of this variant in the UK are presented.

The Potential Clinical Impact of Implementing Different COVID-19 Boosters in Fall 2022 in the United States

This analysis demonstrated that vaccinating with the bivalent mRNA-1273.214 in September consistently prevented more cases of infection and hospitalization than the other two strategies, and concluded that there is no advantage to delay boosting until a BA.4/5 vaccine is available; earlier boosting with mRNA- 1273.

Bounding the levels of transmissibility & immune evasion of the Omicron variant in South Africa

Using detailed laboratory and epidemiological data from South Africa, the constraints on these two characteristics of the new variant of concern, Omicron, and their relationship are estimated and associated uncertainties are estimated to inform projection and scenario modeling analyses.



Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.

It is shown that neutralization level is highly predictive of immune protection, and an evidence-based model of SARS-CoV-2 immune protection that will assist in developing vaccine strategies to control the future trajectory of the pandemic is provided.

Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and monoclonal antibodies

In vitro findings using authentic SARS-CoV-2 variants indicate that in contrast to the currently circulating Delta variant, the neutralization efficacy of vaccine-elicited sera against Omicron was severely reduced highlighting T-cell mediated immunity as essential barrier to prevent severe COVID-19.

SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection

This work investigated whether Omicron escapes antibody neutralization elicited by the Pfizer BNT162b2 mRNA vaccine and whether the virus still requires binding to the ACE2 receptor to infect cells, and tested the ability of plasma from BNT 162b2 vaccinated study participants to neutralize Omicrons versus ancestral D614G virus in a live virus neutralization assay.

Enhancing response to Omicron SARS-CoV-2 variant: Technical brief and priority actions for Member States

  • Biology
  • 2022
Omicron is a highly divergent variant with a high number of mutations, including 26-32 mutations in the spike protein, some of which were likely to be associated with humoral immune escape potential and higher transmissibility.

Seropositivity in blood donors and pregnant women during the first year of SARS‐CoV‐2 transmission in Stockholm, Sweden

Seropositivity levels in metropolitan in Stockholm had reached approximately one in five persons, providing important baseline seroprevalence information prior to the start of vaccination, supporting that mild infection engenders a competent B‐cell response.



  • 2021

Preliminary Report -Early release, subject to modification quantification of the neutralization resistance of the Omicron Variant of Concern

  • 2021

Preliminary Report - Early release , subject to modification quantification of the neutralization resistance of the Omicron Variant of Concern

  • 2021